Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4249 trials
Conditions Diabetes Mellitus, Type 2, Depressive Sy...
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

The Michigan Men's Diabetes Project III: Mind \& Motion is an 7-month pilot randomized clinical trial. The investigators are looking to recruit 80 Black men with type 2 diabetes (T2D) (need to have diagnosis for at least one year) that are over the age of 18. Participants also must be under the care of a physician for their diabetes, self report an Hemoglobin A1c (A1C) of 7.0% or more in the last year, be willing to participate in study events (weekly physical activity, exercise and Cognitive Behavioral Therapy (CBT) sessions, group discussion sessions, and in-person health assessments), have reliable internet access (steady internet connection or unlimited data) that will allow them to use a tablet/phone/computer to complete study related tasks, live in the Wayne or Washtenaw County, and have reliable transportation to in-person events. All participants will receive 8 hours/sessions of cognitive behavioral therapy. Participants randomized to the intervention arm will also receive 8 sessions of guided exercise at the same time. Following that they will also receive 8 group discussion sessions that will serve as on-going support. All sessions will be help via Zoom. Additionally, all participants will participate in The 4 health assessments will take place at baseline, 10 weeks, 18 weeks, and 30 weeks.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Behavioral: Cognitive Behavioral Therapy — Cognitive behavioral therapy focuses on the unique needs of men. A culturally adapted CBT program will be administered to participants as it has demonstrated increased effectiveness for marginalized populations. Cognitive Behavioral Therapy (CBT) aligns well with these cultural needs due to its individualized approach, non-judgmental stance, collaborative nature, and emphasis on empowerment through skills building.
  • Behavioral: Exercise — Research demonstrates a preference for physical activity interventions among men with chronic illnesses, while highlighting limited access to fitness facilities in low-income urban areas as a barrier to participation. Online physical activity interventions have shown efficacy and cost-effectiveness in improving health behaviors, with virtual exercise programs for low-income African American populations demonstrating significant reductions in depressive symptoms. Therefore participants will receive exercise to help improve their diabetes self-management behaviors and depressive symptoms.
  • Behavioral: Group Discussions - Ongoing Support — Participants will join group discussions that will serve as on-going support. The small group component is designed to foster self-efficacy, autonomous motivation, and enjoyment by integrating skills building, personal values, spirituality, and goal setting. This approach has shown positive outcomes in previous pilot studies with African American men, serving as a source of vicarious learning and social support.

Primary Outcomes

  • Change in A1C (Screening, Baseline, 10 weeks, 18 weeks, 30 weeks)
  • Change in General Quality of Life (12-Item Short Form Survey (SF-12)) (Baseline, 10 weeks, 18 weeks, 30 weeks)
  • Change in Diabetes-Related Distress (The Type 2 Diabetes Distress Assessment System) (Baseline, 10 weeks, 18 weeks, 30 weeks)
  • Change in Diabetes Quality of Life (Diabetes Quality of Life Instrument) (Baseline, 10 weeks, 18 weeks, 30 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-13
Completion: 2026-09
Eligibility
Age: 18 Years and older
Sex: MALE
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Michigan
Principal Investigators:
  • Jaclynn Hawkins, PhD (PRINCIPAL_INVESTIGATOR) - University of Michigan, School of Social Work
Contact Information
Study Contact:
Jaclynn Hawkins, PhD
(734) 615-2817
jachawk@umich.edu
Hannah Burgess, MPH
(734)-210-1756
hlburges@umich.edu
Jaclynn Hawkins, PhD
(734) 615-2817
jachawk@umich.edu
University of Michigan
Interventions
  • Behavioral: Cognitive Behavioral Therapy — Cognitive behavioral therapy focuses on the unique needs of men. A culturally adapted CBT program will be administered to participants as it has demonstrated increased effectiveness for marginalized populations. Cognitive Behavioral Therapy (CBT) aligns well with these cultural needs due to its individualized approach, non-judgmental stance, collaborative nature, and emphasis on empowerment through skills building.
  • Behavioral: Exercise — Research demonstrates a preference for physical activity interventions among men with chronic illnesses, while highlighting limited access to fitness facilities in low-income urban areas as a barrier to participation. Online physical activity interventions have shown efficacy and cost-effectiveness in improving health behaviors, with virtual exercise programs for low-income African American populations demonstrating significant reductions in depressive symptoms. Therefore participants will receive exercise to help improve their diabetes self-management behaviors and depressive symptoms.
  • Behavioral: Group Discussions - Ongoing Support — Participants will join group discussions that will serve as on-going support. The small group component is designed to foster self-efficacy, autonomous motivation, and enjoyment by integrating skills building, personal values, spirituality, and goal setting. This approach has shown positive outcomes in previous pilot studies with African American men, serving as a source of vicarious learning and social support.
Study Locations (1 sites)
University of Michigan, Ann Arbor, Michigan 48109 United States
Eligibility Criteria
Inclusion Criteria: * African American/Black males * age 18 years or older * ambulatory status * diagnosis of Type 2 Diabetes (T2D) for one year duration or longer * be under the care of a physician for their diabetes, self report an A1C of 7.0% or more in the last year * be willing to participate in study events (weekly physical activity, exercise and CBT sessions, group discussion sessions, and in-person health assessments) * have reliable internet access (steady internet connection or unlimited data) that will allow them to use a tablet/phone/computer to complete study related tasks * live in the Wayne or Washtenaw County\\ * have reliable transportation to in-person events Exclusion Criteria: * stage 2 hypertension as defined by Joint National Committee (JNC) VIII * recent cardiac events * recent laser surgery for proliferative retinopathy * history of stroke * lower limb amputation * peripheral neuropathy * severe Chronic Obstructive Pulmonary Disease (COPD) (e.g., basal oxygen) * class III or IV heart failure * medical instability. Per American College of Sports Medicine (ACSM) guidelines, medical exclusion criteria will also include currently experiencing: * ongoing unstable angina * uncontrolled cardiac arrhythmia with hemodynamic compromise * active endocarditis * symptomatic severe aortic stenosis * acute myocarditis or pericarditis * acute aortic dissection * acute pulmonary embolism * pulmonary infarction * deep venous thrombosis * physical disability that precludes safe and adequate testing * chest discomfort with exertion * unreasonable breathlessness, or dizziness, fainting, or blackouts. As part of the screening process, the investigators will ask the participant to self-report on these conditions. Participants who are currently receiving psychotherapy services for the treatment of depression from a mental health provider will be excluded. Participants who are currently receiving only medication management from a psychiatrist will be included. If you are interested in the study, please complete our screening survey: https://redcapproduction.umms.med.umich.edu/surveys/?s=JNPPEDANX7KLPPF9. Thank you so much!
Conditions Type 2 Diabetes
Phase PHASE1
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

In this study, we will test the hypothesis that distinct mechanisms account for the SGLT2i-induced stimulation of ketogenesis and lipolysis versus endogenous (hepatic) glucose production in patients with type 2 diabetes (T2D) and type 1 diabetes (T1D), and that the increases in ketone production and lipolysis can be prevented by concomitant administration of the thiazolidinedione pioglitazone. We will conduct five distinct experiments to test this hypothesis in patients with T2D and T1D. MAIN STUDY: To examine the effect of empagliflozin versus empagliflozin/pancreatic clamp on EGP (6,6, D2-glucose), gluconeogenesis (D2O), lipolysis (U-2H-glycerol), ketogenesis (13C-palmitate conversion to 3-betahydroxybuyrate), and norepinephrine turnover (3H-NE) in type 2 diabetes subjects.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Basic Science Masking/blinding: Triple

Interventions / Regimen

  • Drug: Empagliflozin 25 MG — A medication used in the management and treatment of type 2 diabetes mellitus. It is in the sodium-glucose co-transporter (SGLT-2) class of medications.
  • Other: Placebo — Inert tablet

Primary Outcomes

  • Endogenous Glucose Production (EGP) (0 and 300 minutes)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2023-10-05
Completion: 2027-06-30
Eligibility
Age: 30 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Texas Health Science Center at San Antonio
Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Principal Investigators:
  • Ralph DeFronzo, MD (PRINCIPAL_INVESTIGATOR) - The University of Texas Health Science Center at San Antonio
Contact Information
Study Contact:
Ralph DeFronzo, MD
210-567-6691
defronzo@uthscsa.edu
Aurora Merovci, MD
210-567-6691
merovci@uthscsa.edu
Ralph DeFronzo, MD
210-358-7200
defronzo@uthscsa.edu
Texas Diabetes Institute/UH
Interventions
  • Drug: Empagliflozin 25 MG — A medication used in the management and treatment of type 2 diabetes mellitus. It is in the sodium-glucose co-transporter (SGLT-2) class of medications.
  • Other: Placebo — Inert tablet
Study Locations (1 sites)
Texas Diabetes Institute/UH, San Antonio, Texas 78229-3900 United States
Eligibility Criteria
Patients with T2D Inclusion Criteria: * Ages 30-75 * BMI (Body Mass Index) 21-45 kg/m2 * HbA1c = 7.0-11% * eGFR (estimated glomerular filtration rate)\> 60 ml/min/1.73m2 * Blood Pressure (BP)≤160/90 mmHg * Participants must be in general good health based on medical history, physical exam, screening blood chemistries, CBC (Complete Blood Count), TSH/T4 (thyroid/thyroxine hormone), EKG (electrocardiogram), and urinalysis (UA) * Stable body weight (±1.5 kg) over the last 3 months and must not participate in an excessively heavy exercise program * Patients treated with diet, Sulfonylureas, Metformin, or Sulfonylureas/Metformin (Sulfo/MET) * Participants receiving a Glucagon like peptide -1 receptor agonist (GLP1-RA) must be on a stable dose for at least three months prior to study enrollment. * Participants receiving a Dipeptidyl peptidase 4 inhibitors (DPP-4 inhibitor) must be on a stable dose for at least two months prior to study enrollment. * SGLT2 inhibitors must be discontinued at least two months prior to study enrollment. * Statin therapy is permissible if the dose has been stable for at least 3 months EXCLUSION CRITERIA An individual who meets any of the following criteria will be excluded from participation in this study: * Patients treated with Thiazolidinediones (TZDs), or Insulin are excluded. * Patients taking medications other than Sulfonylureas/Metformin (SU/MET), stable dose of GLP1-RA and DPP4i known to affect glucose metabolism are excluded. Patients taking SGLT2i within 2 months of screening visit will be excluded from participating in this study, however they may be asked whether they would agree to discontinue the medication for two months to become eligible. (Please see clarification below.) \* * Subjects with evidence of proliferative retinopathy or estimated glomerular filtration rate (eGFR) \< 60 are excluded * Women of childbearing potential are excluded unless they are taking/using appropriate contractive medications/devices \* Only participants who are taking SGLT2 inhibitors during the prescreening period will be asked to discontinue the medication at least two months prior to the screening visit. If they agree, they will return for an HbA1c measurement four weeks after stopping the SGLT2 inhibitor. If their HbA1c rises to greater than 10%, treatment will be initiated with either metformin, a DPP-4 inhibitor, or a sulfonylurea. We do not anticipate any adverse effects during this initial period, provided the HbA1c remains below 10%. HbA1c will be measured using a fingerstick test, which requires only a minimal amount of blood. No compensation will be provided during this phase. After two months of medication discontinuation, participants will return for a screening visit. If they meet all eligibility criteria, they will be enrolled in the study and payment done by protocol.
Conditions Type 2 Diabetes Mellitus, Type 1 Diabete...
Phase NA
Enrollment 200
Locations 11 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

This multi-center, randomized, cross-over trial will evaluate the efficacy of the Omnipod 6 System compared with the Omnipod 5 System in individuals with type 1 or type 2 diabetes and suboptimal glycemia.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Omnipod 5 System — The Omnipod 5 System with the study CGM
  • Device: Omnipod 6 System — The Omnipod 6 System with the study CGM

Primary Outcomes

  • Time in Range 70-180 mg/dL (13 weeks)
  • Time <54 mg/dL (13 weeks)
  • Time <70 mg/dL (13 weeks)
  • Time >180 mg/dL (13 weeks)
  • Time in Range 70-140 mg/dL (13 weeks)
  • HbA1c (13 weeks)
  • Mean sensor glucose (13 weeks)
  • Time >250 mg/dL (13 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-05-13
Completion: 2027-03-24
Eligibility
Age: 14 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Insulet Corporation
Contact Information
Study Contact:
Trang Ly, MBBS, PhD
978-600-7000
APClinical@insulet.com
Bonnie Dumais, RN
APClinical@insulet.com
Martha Walker
323-605-4442
mawalker@usc.edu
University of Southern California
Interventions
  • Device: Omnipod 5 System — The Omnipod 5 System with the study CGM
  • Device: Omnipod 6 System — The Omnipod 6 System with the study CGM
Study Locations (11 sites)
University of Southern California, Los Angeles, California 90022 United States
Sansum Diabetes Research Institute, Santa Barbara, California 93105 United States
University of Colorado, Aurora, Colorado 80045 United States
Yale, New Haven, Connecticut 06511 United States
Emory University, Atlanta, Georgia 30308 United States
Northwestern University, Chicago, Illinois 60611 United States
Indiana University, Indianapolis, Indiana 46202 United States
Joslin Diabetes Center, Boston, Massachusetts 02215 United States
Henry Ford Health Systems, Detroit, Michigan 48202 United States
Health Partners, Minneapolis, Minnesota 55416 United States
Eligibility Criteria
Inclusion Criteria: * Age at time of consent 14-75 years (inclusive) * Type 1 diabetes diagnosis for at least 6 months or type 2 diabetes diagnosis for at least 1 year, based on Investigator's clinical judgment * Basal/Bolus insulin delivery via multiple daily doses or insulin pump with or without automation * HbA1c ≥ 7.5% * Average # of user-initiated boluses less than 4 per day over the 14 days prior to screening through review of device data or self-reported if non-pump user * Average # of user-initiated boluses less than 4 per day over 14 days, during Standard Therapy Phase through review of device data or self-reported if non-pump user * Currently using a continuous glucose monitor * Willing to use only the following types of U-100 insulin during the study: Humalog U-100, Novolog, Admelog, Kirsty, Fiasp, Lyumjev or their generic equivalents. * Participant agrees to provide their own insulin for the duration of the study * Deemed appropriate for study participation per Investigator's assessment; Investigator has confidence that the participant and/or caregiver can safely operate all study devices and can adhere to the protocol * Deemed appropriate for study participation per Investigator's assessment; Investigator has confidence that the participant and/or caregiver can safely operate all study devices and can adhere to the protocol * If using noninsulin glucose-lowering medications (such as GLP-1 receptor agonist, SGLT2 inhibitor (T2D only), or other) or weight-reduction medications, dose has been stable for 6-weeks prior to screening; and participant is willing to not change the dose unless required for safety purposes. * Willing to wear the system continuously throughout the study * Willing and able to sign the Informed Consent Form (ICF) or has a parent/guardian willing and able to sign the ICF. Assent will be obtained from adolescent participants aged \< 18 years per local regulatory requirements * Able to read and understand English and operate the study device in English * If of childbearing potential, willing and able to have pregnancy testing Exclusion Criteria: * Any medical condition, which in the opinion of the investigator, would put the participant at an unacceptable safety risk * Current or known history of coronary artery disease that is not stable with medical management per investigator judgment, including unstable angina, or angina that prevents moderate exercise despite medical management, or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the 12 months prior to screening * Any planned surgery during the study which could be considered major in the judgment of the investigator * History of severe hypoglycemia in the past 6 months. Severe hypoglycemia is defined as an event that requires the assistance of another person due to altered mental and/or physical status, and requires another person to actively administer carbohydrate, glucagon, or other resuscitative actions. * History of diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS) in the past 6 months, unrelated to an intercurrent illness or infusion failure * Unable to tolerate adhesive tape or has any unresolved skin condition in the area of sensor or pump placement * Blood disorder or dyscrasia within 3 months prior to screening, which in the Investigator's opinion could interfere with determination of HbA1c * Use of hydroxyurea * Plans to receive blood transfusion over the course of the study * Has taken systemic steroids (oral or injectable) within 4 weeks or has had a local steroid injection (e.g. intraarticular, epidural) within 1 week prior to screening or plans to take oral or injectable steroids during the study * Has type 1 diabetes and is taking non insulin glucose lowering medication other than metformin and GLP1, in the 4 weeks prior to screening. * Has type 2 diabetes and is taking sulfonylureas in the 4 weeks prior to screening * Pregnant or lactating, or of childbearing potential and not on acceptable form of birth control (acceptable forms of contraception include abstinence, barrier methods such as condoms, hormonal contraceptives, intrauterine device, surgical sterilization such as tubal ligation or hysterectomy, or vasectomized partner). * Participation in another clinical study using an investigational drug or device within 30-days or intends to participate in any other study during this study period * Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the Investigator's clinical judgment * Participant is an employee of Insulet, an Investigator or Investigator's study team, or immediate family member of any of the aforementioned
Conditions T2DM (Type 2 Diabetes Mellitus), MASLD -...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

This study is designed to evaluate the efficacy, safety, and mechanisms of pulsENDO procedure in patients with T2DM and its effect on MASLD.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: pulsENDO treatment — The pulsENDO procedure utilizes the pulsENDO catheter to deliver non-thermal pulsed electric field to the duodenum to induce cell regeneration. The catheter is introduced to the duodenum through the mouth using a guide wire and the therapy is applied to treat the duodenum under endoscopic visualisation, starting from D4 and repeated proximally. Approximately 10-18 cm of axial length of the duodenum is treated.

Primary Outcomes

  • HbA1c (24 months post-procedure)
  • Improvement of MAFLD (12 months post-procedure)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-09-01
Completion: 2033-08-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chinese University of Hong Kong
Principal Investigators:
  • Stephen Ng, FRCSEd(Gen) (PRINCIPAL_INVESTIGATOR) - Prince of Wales Hospital, the Chinese University of Hong Kong
Contact Information
Study Contact:
Stephen Ng, FRCSEd(Gen)
+85235052956
stephenng@surgery.cuhk.edu.hk
Jenny Study coordinator
+85235052956
jennyho@surgery.cuhk.edu.hk
Stephen Ng, FRCSEd(Gen)
+85235052956
stephenng@surgery.cuhk.edu.hk
Chinese University of Hong Kong
Interventions
  • Procedure: pulsENDO treatment — The pulsENDO procedure utilizes the pulsENDO catheter to deliver non-thermal pulsed electric field to the duodenum to induce cell regeneration. The catheter is introduced to the duodenum through the mouth using a guide wire and the therapy is applied to treat the duodenum under endoscopic visualisation, starting from D4 and repeated proximally. Approximately 10-18 cm of axial length of the duodenum is treated.
Study Locations (1 sites)
Chinese University of Hong Kong, Shatin, Hong Kong
Eligibility Criteria
Inclusion Criteria: * Duration of T2DM \< 10 years * BMI 18.5-40kg/m2 * Failure to achieve adequate HbA1c reduction (7.5 - 11%) after at least 3 months stable dosage of oral glucose lowering drugs Exclusion Criteria: * Previous treatment with pulsENDO or similar procedure * Previous GI surgery that could preclude the ability to perform pulsENDO, or acute gastric and duodenal pathology that increased the risk of pulsENDO * Type 1 DM, DM secondary to specific disease or having any history of ketoacidosis * Patients on insulin * Fasting C-peptide level \<0.5ug/L * Any inflammatory disease of the gastrointestinal tract such as Crohn's disease * Abnormal pathologies or conditions of the gastrointestinal tract, including duodenal polyps, ulcers or upper gastrointestinal bleeding conditions within 3 months of study * Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count less than 100,000/microliter or known coagulopathy * Currently taking prescription antithrombotic therapy (e.g., anticoagulant or antiplatelet agent) within 10 days prior to study and/or there is a need or expected need to use during the study period * Currently taking medications known to cause significant weight gain or weight loss (e.g. chemotherapeutics) * Patients who have used non-steroidal analgesics and anti-inflammatory drugs (NSAID) and corticosteroids in the past 1 month * Underlying uncontrolled endocrine problem that leads to obesity, including and not limited to hypothyroidism, Cushing syndrome and eating disorder. * Patients with contra-indications to endoscopy * Patients with cirrhosis due to causes other than MASLD * Malignancy * Diagnosis of autoimmune connective tissue disorder (e.g. lupus erythematosus, scleroderma) * Pregnant or breast feeding * ASA grade IV \& V * Mental or psychiatric disorder; Drug or alcohol addiction * Other cases deemed by the examining physician as unsuitable for safe treatment * Refusal to participate
Conditions Diabetes (DM), Diabetic Ketoacidosis, Ke...
Phase PHASE1, PHASE2
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

Diabetic ketoacidosis (DKA) is increasingly recognized in adults with "ketone-prone" type 2 diabetes. In many of these patients, the pancreas can still make insulin but becomes temporarily "stunned" during severe, prolonged high blood sugar. Arginine is a naturally occurring amino acid that can trigger the pancreas to release its own insulin when glucose is high. It is FDA-approved for other uses and has been given intravenously for decades with a strong safety record. Whether a single arginine infusion given early during DKA can safely boost the body's insulin and speed recovery has not been tested. This randomized, double-blind, placebo-controlled, phase 1/2 trial will enroll 60 adults who present to one of four Detroit-area emergency departments with DKA consistent with ketone-prone type 2 diabetes (high glucose and significant ketones). Participants will receive standard DKA care ordered by their clinicians. In addition, under blinded conditions they will receive either arginine hydrochloride 30 grams (in 300 mL) or placebo (normal saline), infused intravenously over 30 minutes as early as feasible after DKA is recognized. The main question is whether arginine increases endogenous (self-made) insulin soon after infusion. We will measure C-peptide (a marker released in equal amounts with insulin) and glucose at 10, 30, and 90 minutes after the start of the infusion and calculate the C-peptide/glucose ratio. Secondary measures include the rate of ketone (β-hydroxybutyrate) clearance and the total insulin dose required in the first 24 hours. Additional blood tests will examine arginine and related amino acids, and a small sample of platelets will be used to explore mitochondrial function. Safety will be closely monitored during and after the infusion, and participants will be contacted at 90 days to assess for any delayed problems. Potential risks include temporary flushing, nausea, or headache; the infusion can be stopped at any time if needed. Potential benefits include faster resolution of ketosis and reduced insulin needs, but benefits cannot be guaranteed for individual participants.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Arginine hydrochloride — Single intravenous infusion of arginine hydrochloride 30 g in 300 mL 10% solution (R-Gene® 10), administered over 30 minutes via infusion pump. Given as early as feasible after recognition of DKA and in addition to standard DKA care (fluids, insulin, electrolytes) at the treating clinician's discretion. Investigational pharmacy prepares and dispenses blinded study drug; containers are covered to mask appearance and infusion parameters match placebo. Continuous safety monitoring with prespecified stop criteria. Study blood draws at 0 (pre-infusion), 10, 30, and 90 minutes for C-peptide/glucose and amino acids; clinical labs track β-hydroxybutyrate clearance and total insulin over 24 hours.
  • Drug: Sodium Chloride 0.9% — Placebo comparator: 0.9% sodium chloride administered as a single 30-minute intravenous infusion using identical tubing, pump settings, and covered container as the active arm to preserve blinding. Initiated as early as feasible after recognition of DKA and provided in addition to standard DKA care at the treating clinician's discretion. Study assessments occur on the same schedule as the active arm (0, 10, 30, and 90 minutes) with continuous safety monitoring during and after infusion and follow-up through 90 days.

Primary Outcomes

  • Change in endogenous insulin secretion (C-peptide/glucose ratio) (Baseline (pre-infusion) to 90 minutes after infusion start)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2025-12-19
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: David K Carroll
Collaborators: Wayne State University, Detroit Medical Center
Contact Information
Study Contact:
David K Carroll, M.D.
16175830221
hj7218@wayne.edu
David K Carroll, M.D.
6175830221
hj7218@wayne.edu
Detroit Medical Center
Interventions
  • Drug: Arginine hydrochloride — Single intravenous infusion of arginine hydrochloride 30 g in 300 mL 10% solution (R-Gene® 10), administered over 30 minutes via infusion pump. Given as early as feasible after recognition of DKA and in addition to standard DKA care (fluids, insulin, electrolytes) at the treating clinician's discretion. Investigational pharmacy prepares and dispenses blinded study drug; containers are covered to mask appearance and infusion parameters match placebo. Continuous safety monitoring with prespecified stop criteria. Study blood draws at 0 (pre-infusion), 10, 30, and 90 minutes for C-peptide/glucose and amino acids; clinical labs track β-hydroxybutyrate clearance and total insulin over 24 hours.
  • Drug: Sodium Chloride 0.9% — Placebo comparator: 0.9% sodium chloride administered as a single 30-minute intravenous infusion using identical tubing, pump settings, and covered container as the active arm to preserve blinding. Initiated as early as feasible after recognition of DKA and provided in addition to standard DKA care at the treating clinician's discretion. Study assessments occur on the same schedule as the active arm (0, 10, 30, and 90 minutes) with continuous safety monitoring during and after infusion and follow-up through 90 days.
Study Locations (1 sites)
Detroit Medical Center, Detroit, Michigan 48201 United States
Eligibility Criteria
Inclusion Criteria: * Age \>17 years. * Unscheduled presentation to a participating emergency department with hyperglycemia (serum glucose \>250 mg/dL) and significant ketonemia consistent with DKA, defined as laboratory serum/plasma β-hydroxybutyrate (BHB) \>20 mg/dL (≈≥1.9 mmol/L). Note: point-of-care capillary BHB ≥1.5 mmol/L and/or breath acetone ≥0.01% may be used for screening while confirmatory labs are pending; if confirmatory BHB ≤20 mg/dL, the participant is a screen failure. * Clinical phenotype consistent with ketosis-prone type 2 diabetes (no known prior diagnosis of type 1 diabetes). * Able to provide written informed consent and comply with study procedures in the ED. Exclusion Criteria: * Current renal replacement therapy for chronic kidney disease (hemodialysis or peritoneal dialysis). * Known history of type 1 diabetes mellitus or known GAD65 autoantibody positivity. * Diagnosed cirrhosis/advanced chronic liver disease. * Pregnancy (known pregnancy or positive test at screening). * Known allergy or hypersensitivity to arginine or its components. * Features of at least moderate acute alcohol intoxication at screening, per treating team.
Conditions Dyslipidemia, Atherosclerosis, Diabetes ...
Phase PHASE4
Enrollment 56
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

This is a randomized controlled study to assess the effect of choline fenofibrate compared with policosanol in Korean T2DM patients with asymptomatic atherosclerosis.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Drug: Choline fenofibrate — choline fenofibrate 178.8mg (135mg as fenofibric acid)
  • Drug: Policosanol — policosanol 10mg

Primary Outcomes

  • Carotid intima media thickness (24 week)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2023-06-01
Completion: 2027-12-31
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: false
Enrollment: 56 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Seoul National University Bundang Hospital
Collaborators: Daewon Pharmaceutical Co., Ltd.
Contact Information
Study Contact:
Soo Lim
+82-31-787-7035
limsoo@snu.ac.kr
Minji Sohn
rainbowmjs@naver.com
Soo Lim
01097662706
limsoo@snu.ac.kr
SNUBH
Interventions
  • Drug: Choline fenofibrate — choline fenofibrate 178.8mg (135mg as fenofibric acid)
  • Drug: Policosanol — policosanol 10mg
Study Locations (1 sites)
SNUBH, Seongnam-si, Gyeonggi-do 13620 South Korea
Eligibility Criteria
Inclusion Criteria: * Type 2 diabetes under treatment with HbA1c 6.0-10.0% at screening visit * Male or female of 20 years or over * Mixed dyslipidemia: triglyceride 200\~499 mg/dL, HDL-cholesterol male ≤45 mg/dL or female ≤50 mg/dL * Identified carotid artery plaque: carotid intima-media thickness (cIMT) ≥ 1.0 mm * Creatinine ≤1.8 mg/dL Exclusion Criteria: * Dyslipidemia which requires other therapy: triglyceride ≥500 mg/dL or LDL-cholesterol ≥190 mg/dL * Uncontrolled hypertension * Severe renal dysfunction * GOT/GPT \>120/120 or chronic liver disease * Pregnant or childbearing woman who does not have enough contraception * Changes of medication related to chronic diseases (diabetes, hypertension, dyslipidemia, etc.) within 3 months * Other antiplatlet medication such as cilostazol, clopidogrel (except aspirin)
Conditions Diabetes Mellitus Type 2 (T2DM), Artific...
Phase NA
Enrollment 400
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

Purpose: To evaluate the efficacy of artificial intelligence (AI)-based decision-making technology in managing glycated hemoglobin (HbA1c) and blood glucose levels compared to the control group. Methods: For the AI Intervention group, the patients will be trained to independently use the diabetes telemedicine platform application. Each patient will be equipped with a glucometer and exercise bracelet, and the data will be automatically transmitted to the medical server via Bluetooth. The healthcare platform will analyze the uploaded data and provide feedback suggestions on medication, diet, and exercise automatically. The platform will also monitor the medical and lifestyle data of the patients every two weeks, offer feedback based on the analyses, and remind the patient to adhere to the self-management protocol based on the platform. The platform is a digitally integrated healthcare platform that patients can use independently without the need for monitoring and assistance by healthcare professionals. The glucometer and pedometer bracelet will automatically connect to the platform through Bluetooth. The patient lab sheet identification and structured conversion system, AI for food picture identification and calorie calculation systems, and the AI decision-making system are on the cloud server. Patients upload image information, such as lab sheets and meal pictures, through the patient's diabetes mobile health system, and the cloud platform intelligently analyzes the patient's disease, medication, and daily life status to develop personalized solutions according to individual control goals. Free outpatient visits will be provided to both the intervention and control groups every twelve weeks. For the conventional treatment group, patients will receive a free blood glucometer and will have regular outpatient appointments. There is no limit to the number of outpatient visits; however, they are required to regularly monitor and record their blood glucose, diet, and exercise data to ensure that the medical team objectively conduct their diagnosis and treatment activities. The medical team will provide free outpatient visits every 12 weeks, along with advice on medication, diet, and exercise based on the individual's blood glucose level. Expected results: A significant difference in HbA1c change from baseline to 48 weeks and improved FPG and 2-hour postprandial blood glucose levels in the AI intervention group were observed.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: artificial intelligence — The platform will also monitor the medical and lifestyle data of the patients every two weeks,offer feedback based on the analyses, and remind the patient to adhere to the self-management protocol based on the platform.
  • Other: Routine diagnosis and treatment group for diabetes — There is no limit to the number of outpatient visits for the control group; however, they are required to regularly monitor and record their blood glucose, diet, and exercise data to ensure that the medical team (endocrinologist and nutritionist) objectively conducttheir diagnosis and treatment activities. The medical team will provide free outpatient visits every 12 weeks, along with advice on medication, diet, and exercise based on the individual's blood glucose level.

Primary Outcomes

  • HbA1c (48weeks)
  • Fasting Blood Glucose (FBG) (48 weeks)
  • 2-hour Postprandial Blood Glucose (2hPPG) (48 weeks)
  • Hypoglycemic events (48 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-15
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The First Hospital of Jilin University
Principal Investigators:
  • Chenglin Sun, Doctor (PRINCIPAL_INVESTIGATOR) - The First Hospital of Jilin University
Contact Information
Study Contact:
Chenglin Sun, Doctor
+86 13944855718
clsun213@163.com
Sun
+8688782075
chenglins@jlu.edu.cn
The First Hospital of Jilin University
Interventions
  • Other: artificial intelligence — The platform will also monitor the medical and lifestyle data of the patients every two weeks,offer feedback based on the analyses, and remind the patient to adhere to the self-management protocol based on the platform.
  • Other: Routine diagnosis and treatment group for diabetes — There is no limit to the number of outpatient visits for the control group; however, they are required to regularly monitor and record their blood glucose, diet, and exercise data to ensure that the medical team (endocrinologist and nutritionist) objectively conducttheir diagnosis and treatment activities. The medical team will provide free outpatient visits every 12 weeks, along with advice on medication, diet, and exercise based on the individual's blood glucose level.
Study Locations (1 sites)
The First Hospital of Jilin University, Changchun, Jilin 130000 China
Eligibility Criteria
Inclusion Criteria: * Age: ≥18 years,≤75 years; * Diagnosed with type 2 diabetes for ≥1 year; * 7.0% ≤HbA1c ≤11%; * Body mass index ≥18.5 kg/m2; * Proficient ability to use smart phones; * Agreed to utilize a digital integrated healthcare platform for diabetes care and research; * Informed consents are obtained from the participants. Exclusion Criteria: * Presence of other types of diabetes, such as type 1 diabetes and gestational diabetes; * Severe diabetic complications; * Medical history of chronic liver diseases, including hemochromatosis, hepatocellular carcinoma, autoimmune liver disease, cirrhosis, viral hepatitis (including hepatitis A, B, and C), or hepatolenticular degeneration; * Kidney injury (serum creatinine ≥1.5 times the upper limit of the reference) ; Serum ALT and AST levels elevated \>2-fold; * Medical history of mental disorders, such asschizophrenia, depression, or bipolar affective disorder; * Excessive alcohol intake or drug abuse in the past 3 months; * Use of medications affecting glucose metabolism, such as corticosteroids or ·consumption of immunosuppressive and anti-obesity medications in the past 3 months; * Pregnancy, planning for pregnancy, or lactation; or any other conditions unsuitable for trial participation; * Participatingor plan to participate in other clinical trials; and other cases that are inappropriate to participate.
Conditions Diabetes Mellitus Type 2, Diabetes Melli...
Phase NA
Enrollment 6000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-01
Study Details Design, interventions, and primary outcomes

About This Study

The value of intelligent lifestyle intervention for T2D and its complications has been initially explored, but evidence-based support for the effectiveness of related AI risk prediction models and intervention models remains to be confirmed. The primary objective of this study is to verify the effectiveness of an AI model for predicting the risk of T2D complications based on phenotype, laboratory indicators and wearable device indicators, and to explore the effect and applicability of an intelligent lifestyle intervention model combining wearable devices and smartphones in preventing T2D complications.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: Device: No specific devices — Routine doctor-patient interaction.
  • Other: Device: CGM,CGM management platform — Wearable monitoring + CGM management platform-assisted administration
  • Other: Device: "Professor Tang" WeChat Mini-program — Mini-program-assisted health management
  • Other: Device: CGM, Smart Bracelet, "Professor Tang" WeChat Mini-program — Wearable monitoring + mini-program integrated management

Primary Outcomes

  • HbA1c (Baseline, 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-01
Completion: 2027-10-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 6000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Second Xiangya Hospital of Central South University
Collaborators: First Hospital of China Medical University, The First Affiliated Hospital with Nanjing Medical University, First Affiliated Hospital of Harbin Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, First Affiliated Hospital of Kunming Medical University, Tianjin Medical University, Shanghai 6th People's Hospital, Jinjiang Municipal Hospital, Shanghai Sixth People's Hospital Fujian Campus, Sinocare
Contact Information
Study Contact:
HouDe Zhou, Prof.
86-0731-85292223
houdezhou@csu.edu.cn
周
86-0731-85292223
houdezhou@csu.edu.cn
Second Xiangya Hospital of Central South University
Interventions
  • Other: Device: No specific devices — Routine doctor-patient interaction.
  • Other: Device: CGM,CGM management platform — Wearable monitoring + CGM management platform-assisted administration
  • Other: Device: "Professor Tang" WeChat Mini-program — Mini-program-assisted health management
  • Other: Device: CGM, Smart Bracelet, "Professor Tang" WeChat Mini-program — Wearable monitoring + mini-program integrated management
Study Locations (1 sites)
Second Xiangya Hospital of Central South University, Changsha, China
Eligibility Criteria
Inclusion Criteria: 1. Confirmed diagnosis of Type 2 Diabetes; 2. Aged ≥ 18 years; 3. Able to accept the diabetes management model with AI-assisted management and wearable device monitoring; 4. Able to provide complete lifestyle records, including medical history, medication status, diet, exercise, etc.; 5. Fully understand the purpose, nature, and methods of the study, voluntarily participate in this study, accept a 3-month follow-up, and sign the informed consent form. Exclusion Criteria: 1. Having severe mental illness or language barriers; 2. Suffering from malignant tumors; 3. Pregnant or lactating women; 4. Suspected active infections (such as active pulmonary tuberculosis, pneumonia, etc.); 5. Severe hepatic and renal insufficiency (alanine transaminase and/or aspartate transaminase \> 3 times the upper limit of normal; estimated glomerular filtration rate \< 15 mL/min/1.73 m²); 6. A history of definite major adverse cardiovascular events and/or revascularization and/or intravenous thrombolysis and/or endovascular thrombectomy; 7. Uncontrolled hyperthyroidism or hypothyroidism, pituitary-adrenal dysfunction, or other endocrine diseases; 8. Alcoholism or drug addiction; 9. Receiving insulin therapy; 10. Unable to accept new comprehensive intervention technologies for various reasons (such as personal beliefs, economic factors, etc.).

Sarcopenia in Chronic Lung Diseases

NCT06280443
Recruiting
Conditions Sarcopenia, COPD, Asthma, ILD
Phase Not Applicable
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

Inclusion criteria A)Outpatients with COPD (chronic obstructive pulmonary disease) or ILD (interstitial lung disease) from department of Chest medicine in Taichung Veterans General Hospital, judged by the doctor that they do not need hospitalization or emergent treatment. B) Patients who agree to provide the ID card number to the research team for usage as a link to the National Health Insurance research database and Health bank to explore the continuity of care and the use of medical resources

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • sarcopenia rate (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-11-25
Completion: 2032-09-30
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Taichung Veterans General Hospital
Contact Information
Study Contact:
Pin-Kuei Fu
04-23592525
fpk113@gmail.com
Pin-Kuei Fu, MD, PhD
886-4-23592525
yetquen@gmail.com
Taichung Veterans General Hospital
Interventions
N/A
Study Locations (1 sites)
Taichung Veterans General Hospital, Taichung, 40705 Taiwan
Eligibility Criteria
Inclusion Criteria: 1. Outpatients with COPD (chronic obstructive pulmonary disease) or ILD (interstitial lung disease) from department of Chest medicine in Taichung Veterans General Hospital, judged by the doctor that they do not need hospitalization or emergent treatment. 2. Those who meet the conditions for frailty diagnosis after assessment by the Frailty Scale 3. Patients who agree to provide the ID card number to the research team for usage as a link to the National Health Insurance research database and Health bank to explore the continuity of care and the use of medical resources 4. Age\>=20 Exclusion Criteria: 1. Patients who refuse to sign the consent form 2. Patients who are bed ridden or unable to walk due to physical disabilities 3. Patients with terminal cancer or human acquired immunodeficiency syndrome 4. Patients with edema (pitting edema +2)
Conditions Major Depressive Disorder, Psychedelic E...
Phase NA
Enrollment 112
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is to elucidate if the anti-depressive effect of N,N-dimethyltryptamine (DMT) is based on a biological mechanisms including neuroplasticity and anti-inflammatory effect or due to the subjective psychedelic experience.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: N,N-Dimethyltryptamine — administration of a 2mg/min DMT perfusion over 20 min
  • Drug: Placebo — administration of a placebo perfusion over 20 min
  • Procedure: Propofol — 30 min propofol sedation
  • Procedure: no sedation — no sedation

Primary Outcomes

  • long term changes in depressive symptoms (MADRS) (baseline (before intervention) and on day 14 post-intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-08-05
Completion: 2029-03
Eligibility
Age: 21 Years and older
Sex: ALL
Volunteers: false
Enrollment: 112 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Basel, Switzerland
Principal Investigators:
  • Matthias Liechti, Prof. Dr. med. (STUDY_DIRECTOR) - University Hospital, Basel, Switzerland
  • Felix Müller, PD Dr. med. (PRINCIPAL_INVESTIGATOR) - University Hospital, Basel, Switzerland
Contact Information
Study Contact:
Joyce Santos de Jesus
+41 61 556 65 02
DMT4D@usb.ch
Felix Mueller, PD Dr. med.
+41 61 325 53 94
felix.mueller@upk.ch
University Hospital Basel
Interventions
  • Drug: N,N-Dimethyltryptamine — administration of a 2mg/min DMT perfusion over 20 min
  • Drug: Placebo — administration of a placebo perfusion over 20 min
  • Procedure: Propofol — 30 min propofol sedation
  • Procedure: no sedation — no sedation
Study Locations (1 sites)
University Hospital Basel, Basel, 4031 Switzerland
Eligibility Criteria
Inclusion Criteria: 1. Participants must meet DSM-5 criteria for MDD of at least moderate severity (MADRS≥20). 2. Participants either currently do not use antidepressants or are treated with a stable dose for at least 4 weeks prior to randomization. 3. Age ≥ 21 years old. 4. Sufficient understanding of the German language. 5. Able to understand the study procedures and risks and willing to adhere to the protocol and sign the consent form. 6. Willing not to drive or operate heavy machinery on the treatment day. 7. Willing to refrain from more than 7 standard alcoholic drinks a week, more than 10 cigarettes a day, more than 2 cups of coffee a day, and any illicit substances during study participation. 8. Willing to use effective contraceptive measures throughout study participation. Exclusion Criteria: 1. Past or present bipolar or psychotic disorder, including depressive disorder with psychotic features. 2. First-degree relative with a psychotic or bipolar disorder. 3. Significant prodromal psychotic symptoms (Prodromal Questionnaire-16 symptoms ≥ 6). 4. Psychiatric condition judged to be incompatible with establishment of rapport with study team members and/or safe exposure to DMT, e.g. diagnosed or suspected borderline personality disorder. 5. Current post-traumatic stress disorder or acute stress reaction due to a traumatic event. 6. Post-partum depression. 7. Pregnant or breastfeeding women. 8. Current or recent history of significant suicide ideation or suicide behavior within the past 6 months. 9. Current severe substance use disorder other than nicotine. 10. Planned ketamine, other psychedelic, or electroconvulsive treatment or any such treatment within the past 3 months. 11. Any lifetime use of DMT, use of any other psychedelics within last 3 month or lifetime use of any other psychedelics more than 15 times. 12. Patients who are treated with neuroleptics or known antagonists of 5-HT2 receptors or monoamine oxidase inhibitors (MAOI) and are not able/willing to pause. 13. Increased risk for adverse reactions to propofol or soja products. 14. Increased risk for aspiration. 15. Increased risk for difficult mask ventilation.
Conditions Heart Rate Variability, Anxiety, Depress...
Phase NA
Enrollment 120
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

High anxiety levels may lead to negative outcomes, and previous studies have shown that music listening could reduce periprocedural anxiety and depression. Recent evidence suggests that a lower heart rate variability (HRV) may be associated with anxiety and depression disorders, but the association of these HRV parameters with preoperative mood in the procedural settings are less defined. In this prospective cohort pilot study, the study team will investigate the association between HRV and psychological vulnerability (anxiety, depression) in the presence of music listening before procedures. A total of 120 patients about to undergo procedures (surgery, procedures) will be recruited in three healthcare institutions in Singapore (KK Women's and Children's Hospital, Singapore General Hospital, Changi General Hospital). Patients will be asked to have their ECG readings recorded before, during, and after music listening. Preprocedural information (e.g., demographic, clinical) and psychological scores will be collected.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Device: Electrocardiogram (ECG) monitor — A novel AI-based risk stratification algorithm incorporated into portable platform will be used to monitor and measure patient's ECG, blood pressure, SpO2, and HRV parameters. The platform comprises a tablet application that the clinicians interface with, and coupled with a patient monitoring device with the app that received the real-time patient vital signs to be processed. It requires only a 5-minute 12-lead ECG recording and provides a diagnostic report and risk score on major adverse cardiac events in patients with chest pain complaints. The device is approved as a Class C Medical device by Health Science Authority Singapore for clinical use in Singapore. Three ECG samples for HRV data will be recorded before, during and after music listening, with a sampling rate of 1000Hz, 5-10-minute duration in the supine position and breathing spontaneously to minimise influence from external factors.
  • Other: Music listening — Patients will be given a mobile phone to choose their preferred music to be played during surgery. The music list contains songs across pre-saved playlists spanning different music genres compiled by the institution's music therapist to ensure adequate coverage of the various music genres and to promote relaxation and serenity.

Primary Outcomes

  • Preoperative Heart rate variability (HRV) before, during and after music listening - root mean square of successive differences NN intervals (rMSSD) (1 day)
  • Preoperative Heart rate variability (HRV) before, during and after music listening - low frequency (LF)-HRV (1 day)
  • Preoperative Heart rate variability (HRV) before, during and after music listening - High Frequency (HF)-HRV (1 day)
  • Preoperative Heart rate variability (HRV) before, during and after music listening - LF/HF ratio (1 day)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-08-19
Completion: 2027-12
Eligibility
Age: 21 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: KK Women's and Children's Hospital
Principal Investigators:
  • Ban Leong Sng (PRINCIPAL_INVESTIGATOR) - KK Women's and Children's Hospital
Contact Information
Study Contact:
Ban Leong Sng
65 6394 8436
sng.ban.leong@singhealth.com.sg
Prit Anand Singh
65 6788 8833
singh.prit.anand@singhealth.com.sg
Changi General Hospital
Ban Leong Sng
65 6394 8436
sng.ban.leong@singhealth.com.sg
KK Women's and Children's Hospital
Interventions
  • Device: Electrocardiogram (ECG) monitor — A novel AI-based risk stratification algorithm incorporated into portable platform will be used to monitor and measure patient's ECG, blood pressure, SpO2, and HRV parameters. The platform comprises a tablet application that the clinicians interface with, and coupled with a patient monitoring device with the app that received the real-time patient vital signs to be processed. It requires only a 5-minute 12-lead ECG recording and provides a diagnostic report and risk score on major adverse cardiac events in patients with chest pain complaints. The device is approved as a Class C Medical device by Health Science Authority Singapore for clinical use in Singapore. Three ECG samples for HRV data will be recorded before, during and after music listening, with a sampling rate of 1000Hz, 5-10-minute duration in the supine position and breathing spontaneously to minimise influence from external factors.
  • Other: Music listening — Patients will be given a mobile phone to choose their preferred music to be played during surgery. The music list contains songs across pre-saved playlists spanning different music genres compiled by the institution's music therapist to ensure adequate coverage of the various music genres and to promote relaxation and serenity.
Study Locations (3 sites)
Changi General Hospital, Singapore, Singapore
KK Women's and Children's Hospital, Singapore, Singapore
Singapore General Hospital, Singapore, Singapore
Eligibility Criteria
Inclusion Criteria: 1. America Society of Anaesthesiologist (ASA) 1 to 3 adults undergoing procedures (surgery, pain procedures); 2. Able to read and understand English and/or Chinese; 3. Not receiving opioid prior to the procedures. Exclusion Criteria: 1. With chronic pain; 2. Opioid and drug abuse; 3. Scheduled postoperative Intensive care unit (ICU) admission; 4. With baseline non-sinus heart rhythm or on pacemaker support.
Conditions Anxiety, Pregnancy, Parenting Self-effic...
Phase NA
Enrollment 572
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-30
Study Details Design, interventions, and primary outcomes

About This Study

Emotional regulation is a key component of reducing parenting stress, a sense of self-efficacy, and thus successful parenting, child outcomes, and productivity amongst working parents. However, few interventions begin building these necessary components in pregnancy prior to the extremely stressful period immediately post-partum, where little trait and behavioural modification occurs. More importantly, most interventions overlook the importance of having both partners, despite fathers/partners playing a significant role in influencing maternal stress and mood symptoms. This goal of this study is to examine whether short weekly exercises delivered through a mobile app can help first-time parents feel better emotionally during pregnancy. These exercises are designed to help people manage their emotions and stress. Researchers want to know if doing these exercises, along with getting weekly feedback and encouragement, can reduce signs of depression and improve emotional control. Expecting mothers and fathers who are having their first child may be able to join the study if they meet certain conditions. Participants should be planning to stay in Singapore for the next two years and be comfortable using a smartphone and answering questions in English. Participants may benefit from learning new ways to manage stress and emotions, which could help improve their mental health. Participants will wear a Fitbit watch to track activity. They will complete a short weekly survey about their well-being during pregnancy and a monthly survey about their work productivity until six months after the baby is born. They will also answer online surveys about their health, relationships, and background at the start, three times during pregnancy, and three times after birth. In addition, they will visit the research lab twice to take part in tasks that measure thinking and behaviour.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Group B (Intervention) — Participants in the intervention group will receive recommended modules in the mHealth app installed on their phones.

Primary Outcomes

  • Parents' Depressive Symptoms (Administered upon enrollment, once at 21-24 gestation weeks, once at 28-32 weeks, once at 37-40 gestation weeks, and postnatal 1-, 3-, and 6-months. A composite outcome of the three postnatal EPDS measurements will be used as a primary outcome assessment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-06
Completion: 2028-12-31
Eligibility
Age: 21 Years and older
Sex: ALL
Volunteers: true
Enrollment: 572 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institute for Human Development and Potential (IHDP), Singapore
Collaborators: Duke-NUS Graduate Medical School, National University of Singapore
Principal Investigators:
  • Michelle Z.L Kee, PhD (PRINCIPAL_INVESTIGATOR) - Institute for Human Development and Potential
Contact Information
Study Contact:
Santhi Ponmudi, MPh
+65-64070100
santhi_ponmudi@a-star.edu.sg
Santhi Ponmudi, MPh
+65-64070100
santhi_ponmudi@a-star.edu.sg
Institute for Human Development and Potential (IHDP), Singapore
Michelle Z.L Kee, PhD
Institute for Human Development and Potential (IHDP), Singapore
Interventions
  • Behavioral: Group B (Intervention) — Participants in the intervention group will receive recommended modules in the mHealth app installed on their phones.
Study Locations (1 sites)
Institute for Human Development and Potential (IHDP), Singapore, Singapore, 117609 Singapore
Eligibility Criteria
Inclusion Criteria: Mothers: 1. 21-50 years of age 2. Less than 20 weeks of pregnancy, confirmed by ultrasonography upon enrolment 3. Singleton pregnancy 4. Nulliparous 5. Plan to deliver in Singapore 6. Proficient and able to respond to questionnaires in English 7. Intends for herself and her child to stay in Singapore for the next 2 years 8. Access to a smartphone 9. Willing to download the study app 10. Score of 7 or more in the Edinburgh Postnatal Depression Scale Fathers: 1. 21-75 years of age 2. Proficient and able to respond to questionnaires in English 3. Intends for himself and his child to stay in Singapore for the next 2 years 4. Access to a smartphone 5. Willing to download the study app Exclusion Criteria: Mothers: 1. Any pre-existing or history of psychotic depression, schizophrenia, and bipolar disorders 2. Currently on oral/IV steroids and/or thyroid medication 3. History of thyroid disease 4. Pregnant using assisted reproductive technologies 5. Multiple pregnancies 6. Currently enrolled in interventional randomised controlled trials 7. Responded "Yes, quite often" to EPDS item 10 ("The thought of harming myself has occurred to me") Fathers: 1\. Currently enrolled in interventional randomised controlled trials